Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vandetanib 300 mg vs placebo in RAI-refractory differentiated thyroid cancer
jRCT2080222283Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Nov 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in well-differentiated thyroid cancer (WDTC) comparing Vandetanib 300 mg once daily with Placebo once daily (2 arms). Started Nov 2013; status: completed.
02
Drugs
vandetanib
03
Conditions
well-differentiated thyroid cancer (WDTC)
Beyond the preview
Go deeper on jRCT2080222283.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222283.